New AI app uses ‘selfies’ to generate health diagnostics
By
Aaron Dorman
Jun 26, 2023
The Together app is the first program to use “generative AI” to record a variety of symptoms including blood pressure, heart rate and blood oxygen, according to Renee, the company that introduced it...
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
FDA approves Aurlumyn for severe frostbite
Feb 15, 2024
The newly approved medication lowers the need for amputation of fingers or toes.
AI could make implantable drug delivery a realistic option for many seniors, research suggests
By
Aaron Dorman
Sep 08, 2023
Researchers have proposed an implantable drug delivery system that uses AI to help avoid buildup of scar tissue or autoimmune responses.
Eligibility limited for anti-β amyloid mAbs in seniors with MCI
Aug 18, 2023
Few older adults with mild cognitive impairment or mild dementia were eligible for lecanemab or aducanumab after applying clinical trial criteria.
CMS announces Alzheimer’s drug coverage policy, but ‘the devil is in the details,’ experts say
By
Kimberly Bonvissuto
Jun 01, 2023
A Thursday announcement by the Centers for Medicare & Medicaid Services regarding coverage of Alzheimer’s drugs is being met with skepticism by some industry advocates who say that “the devil is in...